全球智库信息集成服务系统(G2TT): When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity

G2TT

来源类型	Working Paper
规范类型	报告
DOI	10.3386/w18862
来源ID	Working Paper 18862
	When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity
	Michael Kremer; Christopher M. Snyder
发表日期	2013-03-08
出版年	2013
语种	英语
摘要	We argue that in pharmaceutical markets, variation in the arrival time of consumer heterogeneity creates differences between a producer's ability to extract consumer surplus with preventives and treatments, potentially distorting R&D decisions. If consumers vary only in disease risk, revenue from treatments--sold after the disease is contracted, when disease risk is no longer a source of private information--always exceeds revenue from preventives. The revenue ratio can be arbitrarily high for sufficiently skewed distributions of disease risk. Under some circumstances, heterogeneity in harm from a disease, learned after a disease is contracted, can lead revenue from a treatment to exceed revenue from a preventative. Calibrations suggest that skewness in the U.S. distribution of HIV risk would lead firms to earn only half the revenue from a vaccine as from a drug. Empirical tests are consistent with the predictions of the model that vaccines are less likely to be developed for diseases with substantial disease-risk heterogeneity.
主题	Microeconomics ; Market Structure and Distribution ; Health, Education, and Welfare ; Health ; Industrial Organization ; Market Structure and Firm Performance ; Development and Growth ; Innovation and R& ; D
URL	https://www.nber.org/papers/w18862
来源智库	National Bureau of Economic Research (United States)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/576537
推荐引用方式 GB/T 7714	Michael Kremer,Christopher M. Snyder. When Is Prevention More Profitable than Cure? The Impact of Time-Varying Consumer Heterogeneity. 2013.

条目包含的文件
文件名称/大小	资源类型	版本类型	开放类型	使用许可
w18862.pdf（377KB）	智库出版物		限制开放	CC BY-NC-SA	浏览